dc.identifier.citation | McLigeyo, Angela Awino, Godfrey Lule, Fredrick CF Otieno, Joshua Kyateesa Kayima, and Enoch Omonge. "Factors associated with the development of HIV associated lipodystrophy in patients on long-term HAART." Journal of AIDS and 5, no. 12 (2012): 448-454. | en_US |
dc.description.abstract | Highly active antiretroviral therapy is effective in reducing viral load and increasing survival in HIV-1infected
patients. It consists of two nucleoside reverse transcriptase inhibitors and a protease inhibitor
or two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor.
The efficacy of Highly active anti-retroviral therapy (HAART) is however compromised by adverse
events such as lipodystrophy in patients on long-term HAART. This study was carried out in 265 HIV-1
seropositive patients treated with HAART for 6 months and longer, in order to correlate patients’ age,
gender, CD4 counts, WHO stage at initiation of HAART, duration and type of anti-retroviral therapy with
development of lipodystrophy. A longer duration of therapy was found to be significantly associated
with the development of lipodystrophy with 19 patients (24.7%), 73 patients (60.8%) (OR 2.06; CI 1.21 to
3.51, p value 0.004) and 39 patients (67.2%) (OR 2.34; CI 1.21 to 1.46, p value 0.006) having
lipodystrophy at 6 to 18, 18 to 36 and 36 to 72 months of treatment, respectively. The odds of
lipodystrophy after HAART for 18 to 36 months and 36 to 72 months was 4.14 (p < 0.0001) and 6.179 (p <
0.0001) times, respectively, higher than after HAART for 6 to 18 months. There was no association
between age, gender, CD4 counts, WHO stage and the development of lipodystrophy. | en_US |